1-5 of 5
J. Densmore
Close
Sort by
Journal Articles

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

Paul Richardson, A. Jakubowiak, J. Wolf, J. Allerton, J. Zonder, S. Lonial, A. Krishnan, J. Densmore, I. Ghobrial, K. Colson, T. Kendall, C. Leister, B. Martineau, T. Hideshima, T. Facon, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson
Journal: Blood
Blood (2007) 110 (11): 1170.
https://doi.org/10.1182/blood.V110.11.1170.1170
Published: 2007
Journal Articles

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

Paul Richardson, S. Lonial, A. Jakubowiak, A. Krishnan, J. Wolf, J. Densmore, S. Singhal, I. Ghobrial, J. Stephenson, J. Mehta, K. Colson, D. Francis, T. Kendall, N. Obadike, K. Sullivan, J. Martin, T. Hideshima, L. Lai, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Anderson
Journal: Blood
Blood (2007) 110 (11): 1164.
https://doi.org/10.1182/blood.V110.11.1164.1164
Published: 2007
Journal Articles

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, S. Lonial, A. Jakubowiak, J. Wolf, A. Krishnan, J. Densmore, S. Singhal, I. Ghobrial, L. Schwartzberg, K. Colson, J. Harris, T. Kendall, B. Martineau, N. Obadike, K. Sullivan, S. Pearson, T. Hideshima, L. Lai, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K.C. Anderson
Journal: Blood
Blood (2006) 108 (11): 3582.
https://doi.org/10.1182/blood.V108.11.3582.3582
Published: 2006
Journal Articles

Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.

Michael E. Williams, MD, John J. Densmore, MD, PhD, Andrew W. Pawluczkowycz, MS, Paul V. Beum, PhD, Adam D. Kennedy, PhD, Margaret A. Lindorfer, PhD, Susan H. Hamil, RN, Gina R. Petroni, PhD, Jane C. Eggleton, RN, Ronald P. Taylor, PhD
Journal: Blood
Blood (2005) 106 (11): 2970.
https://doi.org/10.1182/blood.V106.11.2970.2970
Published: 2005
Journal Articles

A Pilot Study of Thrice-Weekly Low Dose Rituximab (RTX) in the Treatment of Chronic Lymphocytic Leukemia (CLL) Suggests Enhanced Therapeutic Targeting Compared to Standard Dose Regimens.

Ronald P. Taylor, Ph.D., Andrew W. Pawluczkowycz, M.S., Paul V. Beum, Ph.D., Adam D. Kennedy, M.S., Margaret A. Lindorfer, Ph.D., John J. Densmore, M.D., Ph.D., Jane Eggleton, R.N., Karen L. LoRusso, M.D., Michael E. Williams, M.D.
Journal: Blood
Blood (2004) 104 (11): 2520.
https://doi.org/10.1182/blood.V104.11.2520.2520
Published: 2004